USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/21195
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGuțu, Marina
dc.date.accessioned2022-06-16T12:13:21Z
dc.date.available2022-06-16T12:13:21Z
dc.date.issued2022
dc.identifier.citationGUȚU, Marina. Eye disorders in COVID-19 infection. In: MedEspera: the 9th International Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2022, p.47.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/21195
dc.identifier.urihttps://medespera.asr.md/en/books
dc.description.abstractIntroduction. The COVID-19 pandemia caused by SARS-CoV-2 had led to various lesions of internal organs and systems. SARS-CoV-2 is tropic to the ACE-2 receptor, located on epithelial cells of the mucous membranes of the respiratory tract, vascular endothelial cells, neurons, cornea, limbus, and conjunctiva, etc. The eyes are not the main route of transmission of the virus, however, the presence of the ACE2 protein and communication through the nasolacrimal duct with the nasal cavity increases the risk of ophthalmic manifestations of COVID-19. Aim of study. Literature analysis to highlight the most common clinical ocular manifestations in COVID19 infection. Methods and materials. In the Pubmed and Google Scholar databases, we selected and analyzed 40 articles with embedded keywords: "Eye disorders in COVID-19 infection", "Ocular Symptoms in Coronavirus Disease", etc. Results. Ophthalmic manifestations of Coronavirus infection occur in approximately 6-12% of patients. The most common manifestation of damage to the anterior segment of the eye is conjunctivitis (86.4% of cases). This disease is accompanied by the following clinical picture: dry eyes, hyperemia, chemosis, epiphora, etc. Microvascular retinal disorders increase 8.8-fold in SARS-CoV-2, referring to posterior segment involvement. Venous thromboembolism develops in 19-25% of patients with COVID-19 . It is characterized by retinal hemorrhages, microinfarcts in the internal plexus, cotton spots, occlusion of the central retinal vein, etc. One of the rare manifestations, less than 1% of cases, is damage to the cranial nerves, including the optic nerve. This manifestation may develop as a result of hypoxia, ischemia, inflammation, or immunological response to the optic nerve, causing demyelination. The deadly combination of diabetes mellitus and a positive SARS-CoV-2 test is increasingly common in the longforgotten disease. Conclusion. At the moment, much attention is paid to the treatment of respiratory diseases, thromboembolic complications and neurological symptoms of Coronavirus infection, while ocular complications in patients infected with SARS-CoV-2 are usually not reported or relegated to the background . This leads to the fact that many ophthalmic manifestations and complications of this disease remain unpublished. The combination of these factors leads to the fact that ophthalmic treatment is complicated by an incomplete picture of the data or even occurs without contacting specialists.en_US
dc.language.isoenen_US
dc.publisherNicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova, Association of Medical Students and Residentsen_US
dc.relation.ispartofMedEspera: The 9th International Medical Congress for Students and Young Doctors, May 12-14, 2022, Chisinau, Republic of Moldovaen_US
dc.subjecteye disorders in COVID-19 infectionen_US
dc.subjectocular symptoms in coronavirus diseaseen_US
dc.titleEye disorders in COVID-19 infectionen_US
dc.typeOtheren_US
Appears in Collections:MedEspera 2022

Files in This Item:
File Description SizeFormat 
12._EYE_DISORDERS_IN_COVID_19_INFECTION.pdf218.8 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback